Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer
about
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in miceUnexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsHDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesChemotherapy and chemoprevention by thiazolidinedionesCXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.Specific activity of class II histone deacetylases in human breast cancer cellsIn vivo effects of rosiglitazone in a human neuroblastoma xenograft.Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages.Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanismPeroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator SystemVDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcriptionValproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1.A Role for the PPARgamma in Cancer Therapy.Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy.Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARgamma Dependent and Independent MechanismsClinical Use of PPARgamma Ligands in Cancer.Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines.Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibitionMicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.PPARalpha Ligands as Antitumorigenic and Antiangiogenic AgentsE2F transcription factor-1 regulates oxidative metabolism.Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1.PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cellsPeroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1.DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.Troglitazone induces extracellular matrix and cytoskeleton remodeling in mouse collecting duct cells.Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells.Tumor-suppressive lipoxygenases inhibit the expression of c-myc mRNA coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein 1 in human prostate carcinoma PC-3 cells.The CDK4-pRB-E2F1 pathway controls insulin secretion.New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha) upregulated E-cadherin expression in HepG2 cells.Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.
P2860
Q21142723-1232EBFF-D03C-4CB6-BAD8-8F354FF8A036Q26750845-D18FEC03-54C8-420C-8F89-5A2E8DBFFD81Q26766640-DE929649-77DA-4190-9E62-829072818CDEQ27011352-AB9A51D2-E3D9-4237-AB8A-7051A40BF2D9Q30436563-78183D0F-D9BF-4140-84D3-2600A9D57BE9Q33606021-FE8B3AC8-5B53-4651-8CBC-679A6C267C4DQ33723620-E5F28304-F651-4481-83B4-C4F28B2E6DB6Q33748699-D61B028B-7FC3-40F8-B2B0-3992BFACB061Q34094960-626EFB93-8CC5-4316-B496-838F5BA9D9E7Q34575446-B2D86CBC-8C1F-422D-9BDE-5C1136D1C5F7Q34646050-9BD15578-846E-437C-87BF-DFC221442C80Q35124419-AE2CC06F-BCBD-4437-81F7-2EC0B8C959D1Q35495620-0B825958-1D6F-49F7-8E34-CCB56A8DCCBBQ36216675-FF9FA85C-AD80-4594-B7BB-8A89429F82B8Q36606222-1BCD0B43-87F8-4A37-A912-FE4509BE6110Q36691611-6865B96B-DD2E-4B15-929C-6F925A93445CQ36822431-582A8A85-B69A-42B5-B3E3-86C8CD3D688FQ36890814-DA1660C7-70F3-49AD-BE12-D94F37A93FF5Q37021288-7EDDDEC9-9F9A-4E6A-86B7-2963C08BF356Q37110658-0EDE1300-CD56-43A8-8826-AA2E93043AE9Q37122334-EC137567-D5AD-4EAD-A54C-CD8E6B73A96AQ37162405-903D98E4-F84B-450E-8B42-4625BAF2C9B1Q37182802-0FC71607-7615-4370-A281-FB350498D8D8Q37251719-1408D3A1-BB5C-42AD-8409-34F0F17680AFQ37361979-5F1A91A8-30C0-4AF9-B345-065F9E483FC0Q37416288-FB88B440-E7F4-4195-A8D2-A64C7CA4A9E0Q37493920-F61DBE5E-1A2B-4CF8-993F-D6AFF41BA408Q37656960-AB0B5FAE-D28F-4144-84AA-D614191E1B5BQ38318725-1264CD5F-9249-4A8A-A6C5-57B718994FEEQ39185282-D9F811A7-787E-4183-810B-2970E236BCD7Q39200334-BDCE0223-86F1-42CB-88B4-94BC77B3D758Q39204978-2AE122E2-E4DE-4EB5-8D45-38C2833151B9Q39364983-465E197B-672D-4CEF-8510-386081531C4CQ39522931-9ADC8EBC-D512-4103-ADA4-788D5AB6E76AQ39583323-E713C18F-8DCD-49D8-94BA-C7A82B2988B5Q39815729-907BE78C-B0B5-4318-A3CA-CB679BB8B1D9Q39825696-A1701F9A-92E7-40CC-A20D-DD5C57054DB8Q40014273-A69F6A30-F6AF-43FA-8B06-B289D4ACBB94Q40017817-66711FBD-E9DC-48A8-902E-DEF80CD12B86Q40088730-F389F062-2929-4295-B4D6-B47373C816AD
P2860
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Peroxisome proliferator-activa ...... nd invasion of prostate cancer
@en
Peroxisome proliferator-activa ...... d invasion of prostate cancer.
@nl
type
label
Peroxisome proliferator-activa ...... nd invasion of prostate cancer
@en
Peroxisome proliferator-activa ...... d invasion of prostate cancer.
@nl
prefLabel
Peroxisome proliferator-activa ...... nd invasion of prostate cancer
@en
Peroxisome proliferator-activa ...... d invasion of prostate cancer.
@nl
P2093
P2860
P356
P1476
Peroxisome proliferator-activa ...... nd invasion of prostate cancer
@en
P2093
Anna Abella
Arnaud Pillon
Danièle Noël
David Sarruf
François Iborra
Irena Iankova
Lluis Fajas
Marie-Laurence Berthe
Pierre Dubus
Stéphane Culine
P2860
P304
P356
10.1128/MCB.00605-06
P407
P577
2006-10-01T00:00:00Z